Shanghai Henlius Biotech announced it would price its Hong Kong IPO to raise as much as $477 million, valuing the company at up to $3.5 billion. Henlius, which was formed as a JV between Fosun Pharma and US-based Henlius, is the biologic arm of Fosun, which owns 60% of the company. It is developing a portfolio of biosimilars, bio-betters and innovative biologics. In February, Henlius was approved to market a biosimilar to Roche’s Rituxan, a treatment for lymphoma. It is the first approval for Henlius and the first biosimilar approved in China. Source: China Biotoday
